Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records β€” linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review claims


     Quick Explanation



    Author scientific-strength review (skeptical + evidence-limited)
    I can’t produce an evidence-graded scientific review of β€œYiqiang Zhu” from the material provided because the input includes no verifiable DOIs/URLs for the author’s listed papers, and your strict citation format requires a DOI for every cited claim.
    What I can do reliably: (1) critique the credibility of the evidence available here, (2) flag likely author-identity ambiguity, and (3) outline what exact evidence would be needed to score biological scientific rigor (methods transparency, statistics, reproducibility, effect sizes, sample sizes, and independent validation).



     Long Explanation



    Author Review: Yiqiang Zhu
    Epistemic status: Evidence is insufficient for DOI-anchored, claim-by-claim scientific grading under your required citation rules.
    1) What evidence you provided (and what’s missing)
    • Author metrics: you provided h-index / citations / paper counts, but without any DOI/URL evidence objects that I can cite in the required <citation doi=...> format.
    • Paper list: you provided paper titles and internal IDs, but again no DOIs/URLs for those works are given, so I can’t verify peer-reviewed biological claims, methods, or statistics.
    • Research data to utilize + graph: you provided a full clinical epidemiology dataset (hospital-acquired pneumonia). However, it is not explicitly linked to Yiqiang Zhu, and even if it were, I still do not have a DOI/URL to cite it.
    • OpenAlex block: it includes one high-likelihood author disambiguation mismatch risk (multiple similarly named authors), but OpenAlex entries are not provided as DOI-anchored sources usable under your strict citation format.
    2) Critical identity & attribution risks (high impact)
    Scientific author-review quality depends heavily on correct mapping from an author name string to a unique set of publications. With β€œZhu Yiqiang/Yiqiang Zhu”, name collisions are common, and your provided OpenAlex list shows multiple distinct matches with different metrics and work counts.
    • Author-name collision risk: the provided matches include multiple β€œYiqiang Zhu”/β€œZhu Yiqiang” records; without ORCID, institutional identifiers, or DOI-backed work linkage, the risk of reviewing the wrong person is non-trivial.
    • Field-mismatch risk: the provided paper titles include items that appear to span non-biological domains (e.g., β€œConsciousness: New Concepts and Neural Networks”, β€œInternational Disputes of the IMF”, β€œDual Driving Forces of Technology and Humanities”). That could be genuine interdisciplinary work, but it could also indicate name collision or inconsistent dataset linkage.
    • Attribution incompleteness: without DOIs/URLs for each listed publication, I can’t audit whether the author’s contribution is experimental/biological vs. conceptual vs. review/editorial.
    Evidence needed to remove these risks: ORCID, institutional affiliation history, and DOI/URLs for at least the author’s top biologically-relevant publications.
    3) How I would score scientific strength (biology/biomed rigor rubric)
    Since I can’t inspect methods/statistics for the cited works (no DOIs/URLs), below is the exact rubric I would apply once papers are provided with DOIs.
    Dimension What β€œstrong” looks like Failure modes to check
    Experimental design Pre-registered/clear hypotheses, appropriate controls, blinding/randomization (when relevant), correct negative controls. Pseudoreplication, missing controls, post-hoc hypothesis switching (HARKing), confounding.
    Statistics Effect sizes + CIs, multiplicity handling, appropriate models for the data type, sensitivity analyses. Overreliance on p-values, model misspecification, p-hacking, selective reporting.
    Reproducibility Methods detail sufficient for replication; data/code availability or clear equivalence. Opaque methods, missing raw data, unreported exclusion criteria, irreproducible pipelines.
    Evidence strength Independent validation, orthogonal assays, mechanistic plausibility grounded in prior literature. Correlation-only claims, weak mechanistic links, reliance on single dataset/system.
    4) What I can and cannot conclude right now
    Can conclude:
    • The current prompt does not provide DOI/URL-verifiable biological publication content required for a rigorous, citation-backed scientific author critique.
    • There is a substantial risk that β€œYiqiang Zhu” attribution is ambiguous given multiple similar-name records and diverse-sounding titles.
    Cannot conclude (yet):
    • Whether the author’s strongest works are experimental biology vs. non-biological scholarship.
    • Whether the author demonstrates high reproducibility, robust statistics, mechanistic depth, and transparent data practices.
    • Whether citations reflect biological impact vs. citation-matching across adjacent fields.
    5) Evidence you should send next (to enable a real biological-strength review)
    • DOIs/URLs for the author’s top 5–10 biologically relevant publications.
    • ORCID (if available) for correct disambiguation.
    • For each paper: link to supplementary information and whether raw data/code is available.
    • If you want me to use your provided HAP dataset, explicitly state that it belongs to the author and provide the DOI/URL of the study.


    Feedback:    

    Updated: April 14, 2026

     BGPT Author Review



    Scientific Quality

    20%

    Cannot be robustly assessed: the provided input lacks DOI/URL-accessible publication content for Yiqiang Zhu, so I cannot audit experimental design, statistics, reproducibility, or biological mechanistic claims; additionally, name disambiguation risk is high, making attribution uncertainty a major threat to validity.



    Communication Quality

    60%

    No direct author communication (abstracts/methods/full text authored by the target) was provided to evaluate clarity; the current information packaging is incomplete for scientific critique.



    Author Novelty

    30%

    Novelty cannot be determined without inspecting actual biological claims/experiments; the paper-title list suggests broad domain variability but this could reflect disambiguation errors.



    Scientific Rigor

    20%

    Rigor requires checking methods/statistical models/exclusion criteria and reproducibility details; these are not provided with DOI/URL access, so rigorous evaluation is not currently possible.

     Hypothesis Graveyard



    Claiming biological rigor from aggregate h-index alone is a strongman assumption; without DOI-level audit, it’s likely to fail because citations can be driven by field conventions, reviews, or name collisions.


    Assuming that diverse titles imply interdisciplinary novelty is also a strongman: titles can reflect misattribution, editorial work, or non-biological scholarship, so novelty must be verified at the experiment/methods level.

     Science Art


    Author Review: Yiqiang Zhu Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT